Can Schrödinger (SDGR) Stock Reach $33?

Schrödinger, Inc. (SDGR) is a computational drug-discovery company that builds a physics-based software platform used to design novel molecules for pharmaceuticals and materials science. After a sharp rally through late 2026, investors are asking whether the stock can extend toward a $33 price target. The answer depends less on a single catalyst than on whether the company's software momentum and lumpy collaboration revenue can sustain analyst enthusiasm.

Key Takeaways

• The central target of $33 is the average of the verified analyst price targets that sit above the current share price, not a published Street consensus.
• Five current targets were reviewed, spanning roughly $29 to $36; the overall mean of all five is about $32.
• The latest verified price of about $29.82 leaves roughly 11% upside to the $33 central target, a modest move.
• Strongest supports are accelerating software demand, a fourth-quarter guidance raise, and a wave of analyst target increases tied to AI-driven drug discovery.
• Biggest risks are volatile collaboration revenue, ongoing operating losses, competition, and a valuation that already prices in high expectations.
• For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages to track developments as they unfold.
• You can also monitor automated, AI-driven stock ideas through Trending AI Robots.

Analyst Price Targets and Consensus View

Five credible, current analyst price targets were reviewed. Because the arithmetic mean of all five (about $32.40) sits only about 7% above the latest price, the central target used here is the average of the targets that are above the current price, per a minimum-distance rule. Those four above-price targets average $33.25, rounded to $33. For context, the overall mean of all five valid targets is roughly $32, and the full range runs from $29 to $36.

The targets diverge on conviction. TD Cowen (Buy, $36, raised from $31) and BMO Capital (Outperform, $35) are the most bullish, citing a strong software outlook and progress toward hosted contracts. KeyBanc (Overweight, $32) points to interest in AI-driven drug discovery. On the cautious side, UBS (Neutral, $30) and Morgan Stanley (Equal Weight, $29, raised from $17) acknowledge improved software traction but flag elevated expectations and limited near-term catalysts. This spread—bullish software momentum versus cautious valuation—explains the relatively wide range.

Current Market Position and Path Toward the Target

With the stock around $29.82 at the November 6, 2026 close, reaching $33 implies roughly 11% upside, a modest move by equity-market standards. The path would most likely run through continued strength in the software business. Schrödinger recently reported a fourth-quarter beat in annual contract value (ACV) and raised full-year 2026 guidance at the midpoint, while a structure milestone supported third-quarter revenue. Because the collaboration segment is inherently lumpy, quarter-to-quarter results can swing sharply even as the recurring software base grows.

What Could Support a Move Toward the Target

• Software momentum: A 4% ACV beat and a guidance raise signal growing traction for the platform.
• AI drug-discovery theme: Several analysts cited rising interest in AI-driven research as a reason for lifting targets.
• Strategic partnerships: Collaborations with major pharmaceutical partners, including Novartis and Eli Lilly, validate the platform's commercial relevance.
• Analyst revisions: Multiple firms raised targets in October and November 2026, a generally constructive signal.
• Expanding applications: Research extending the platform into areas such as battery electrolytes broadens the addressable market.

What Could Prevent the Target From Being Reached

• Lumpy collaboration revenue: Discovery revenue tied to milestones and collaborations can swing quarter to quarter.
• Ongoing losses: The company has reported losses in most recent years as it invests in research and development.
• Elevated expectations: Morgan Stanley and UBS caution that much of the good news may already be reflected in the price.
• Valuation compression: A price-to-sales multiple near 6.9x leaves little room if growth disappoints.
• Competition and clinical risk: Computational drug-discovery rivals and the uncertain outcome of internal pipeline programs remain headwinds.

Technical Levels and Market Structure

The stock's climb from the mid-teens to near $30 reflects a powerful momentum move that has carried shares above several prior average analyst targets. The round-number $30 level now serves as a psychological pivot: holding above it would keep the near-term uptrend intact, while slipping back below could signal that the rally has stalled. Beyond that, durable support and resistance zones are less clearly defined after such a rapid advance, so investors should treat current technicals as momentum-driven rather than anchored in long-standing price history.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different assumptions and timelines. Key items to watch include the next quarterly earnings release and any updates to guidance, further analyst target revisions, new partnership or licensing announcements, and data from the internal clinical pipeline. Broader conditions in the biotech and healthcare-IT sectors—especially funding and AI-related sentiment—will also influence how the stock trades relative to the $33 target.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This approach can help traders surface opportunities, track existing positions, and identify shifting trends more efficiently than manual screening alone. For those seeking a systematic complement to fundamental research, exploring these signals can add a useful layer to the decision-making process.

Final Assessment

The $33 central target—an average of the analyst targets above the current price—requires roughly an 11% advance from about $29.82, a modest but not automatic move. The case for it rests on strengthening software demand, a guidance raise, and a favorable AI drug-discovery narrative that has driven a cluster of target increases. The counterargument is equally clear: collaboration revenue is volatile, the company remains unprofitable, and some analysts warn that expectations already run high, with the full analyst range stretching from $29 to $36. The most important signals ahead will be sustained software growth, guidance follow-through, and any evidence that the platform's momentum extends beyond a single strong quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations